Latest Research And Development News

Page 7 of 115
PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.
Ada Torres
Ada Torres
29 Oct 2026
Dimerix has more than doubled its cash balance after an Everest Medicines licensing payment and a drawdown from a secured funding facility. The ASX-listed biotech is also advancing its fully recruited Phase 3 trial while preparing a second kidney drug for Phase 2 testing.
Ada Torres
Ada Torres
29 Oct 2026
Omega Oil & Gas has reported its strongest appraisal quarter yet, with Canyon-3 and Canyon-4 confirming thick, stacked oil and gas-bearing intervals in Queensland’s Taroom Trough. The company has also expanded its operated acreage to 2,976 square kilometres while retaining $92.9 million in cash and no debt.
Victor Sage
Victor Sage
29 Oct 2026
Hawsons Iron has confirmed a 69.3% Fe magnetite concentrate in bulk testwork and identified a possible second iron product from the processing waste stream. The gains arrive alongside a $1.23 million capital raise, but quarter-end cash covered only 1.22 quarters of reported outgoings before a later tax incentive receipt.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Skin Elements has converted its New Zealand Farmlands agreement into a first NZ$150,000 ECO-Nurture delivery, while A$900,000 in placement proceeds lifted quarter-end cash to A$1.455 million. The commercial progress comes alongside a cost review and a regulatory hurdle still standing between the company and broader national sales.
Ada Torres
Ada Torres
29 Oct 2026
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026
Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.
Ada Torres
Ada Torres
28 Oct 2026
Biotron’s BIT-HBV001 produced up to a 99.7% reduction in HBV-DNA in cell-based studies, while combination testing with Myrcludex B showed antiviral synergy. The company is also refining SedRx’s European regulatory pathway, but had A$1.06 million in cash at quarter-end, equivalent to 2.15 quarters of funding at the latest operating burn rate.
Ada Torres
Ada Torres
28 Oct 2026
Ocean Sciences has committed A$100,000 to a 12-month research program testing whether Sargassum-derived alginate can recover gold, silver and potentially rare earth elements from retired data centre hardware. The project gives the seaweed company a new industrial angle, but remains firmly at the laboratory stage.
Victor Sage
Victor Sage
28 Oct 2026
RooLife Group opened FY2027 with A$7.9 million in unaudited revenue and customer cash receipts up 884% year on year. The stronger quarter comes as its Aurora renewable energy division shifts from acquisition and product development towards project execution, although operating cash flow remains negative.
Victor Sage
Victor Sage
28 Oct 2026
Epiminder says its $65.1 million cash balance can fund the DETECT study and next-generation Minder device into 2028, despite a higher quarterly operating outflow. The company also paid $3.5 million to major shareholder Cochlear for research and development during the quarter.
Ada Torres
Ada Torres
28 Oct 2026
Latrobe Magnesium has completed its fully underwritten $3.4 million entitlement offer, with sub-underwriters absorbing roughly 91% of the available shares. The company says the funding carries its Victorian demonstration plant through to targeted first magnesium production by the end of 2026.
Victor Sage
Victor Sage
28 Oct 2026

Browse the archive

Full archive